Sogroya Европейски съюз - италиански - EMA (European Medicines Agency)

sogroya

novo nordisk a/s - somapacitan - crescita - ormoni ipofisari e ipotalamici e analoghi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).